30 June 2013
Corneal inlays are designed to treat presbyopia by being inserted in the non-dominant eye and correcting for near vision; distance vision remains (mostly) unaffected.
04 February 2013
Nanotechology, which involves controlling matter at the molecular and atomic levels, was a much-hyped investment theme a decade ago. It’s since become widely used in commercial products ranging from solar panels to semiconductors, but investing in nanotech requires patience.
01 February 2013
Tracey Sunderland, COO, Coda Therapeutics Inc: “We think we’ve got something that has the potential to be a real game changer in this space particularly due to the fact that there are no therapeutic compounds on the market currently.”
09 January 2013
CoDa Therapeutics, Inc. today announced positive results from a Phase 2b clinical trial of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is an easy to administer, once-a-week, topical, drug candidate being developed for the treatment of chronic wounds. It is designed to increase the incidence of wound healing compared to existing therapeutic techniques, and to heal them much faster. The company believes these results support advancing NEXAGON into Phase 3 registration trials. Venous leg ulcers are increasingly common and costly, and can be a cause of prolonged suffering for patients.
07 January 2013
Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RMI), and co-investors.
24 July 2012
CoDa Therapeutics, Inc. announced today that it raised an additional NZ$24.5M from Russian investment firm RusnanoMedInvest (“RMI”). This brings the company’s total Series B Round to nearly NZ$49 million following a first close late last year.
06 October 2011
Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, is pleased to partner with CoDa Therapeutics, Inc. in providing a $6 million term loan.
29 April 2011
Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,858,609 entitled, "Solid ganaxolone formulations and methods for the making and use thereof." The patent describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of ganaxolone and will provide coverage until the end of 2026.
18 April 2011
San Diego, California - April 18, 2011 - CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing.
17 April 2011
Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with ganaxolone treatment may eliminate the behavioral symptoms associated with FXS.
03 July 2020
03 July 2020
02 July 2020
02 July 2020